Expression of OVA by Mtecs leads to deletion of a polyclonal repertoire of OVA-specific CD8 T cells. (A) OVA is selectively expressed in Mtecs in RIP-mOVA thymuses. Ctecs and Mtecs from RIP-mOVA thymus were enriched and expression of OVA was investigated by real-time PCR. Cathepsin L (Cat L), cathepsin S (Cat S), and insulin were monitored as controls for cell purity. Ctecs expressed high levels of cathepsin L, low levels of cathepsin S, and no insulin. Meanwhile, Mtecs expressed low levels of cathepsin L, high levels of cathepsin S, and insulin (reference 3). (B) Grafting Vβ5 BM (CD45.2) into lethally irradiated B6 or RIP-mOVA recipients generated [Vβ5→B6] or [Vβ5→RIP-mOVA] BM-chimeric thymuses. 8 wk after BM transfer, 106 CD8 thymocytes were transferred into wild-type, congenically marked B6 mice (CD45.1). 1 d later, these mice were immunized with rLmOva. 7 d after immunization, splenocytes were isolated and their ability to produce IFN-γ was determined in response to a 5-h incubation with OVA peptide or medium alone. This experiment was performed twice with two mice per group. (C) IFN-γ and CD45.2 staining on gated CD8 T cells. Trasfer of thymocytes from [Vβ5→B6] is shown in the left panels. Transfer of thymocytes from [Vβ5→RIP-mOVA] is shown in the right panels. Numbers below indicate percentages of cells in each quadrant. Vβ5 transgenic donor-derived CD8 T cells are CD45.2+, whereas host-derived CD8 T cells are CD45.2−.